Lyn M. Moir

PO Box M77, Missenden Rd
NSW 2050, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Prospective nanoparticle treatments for lymphangioleiomyomatosis.

Prospective nanoparticle treatments for lymphangioleiomyomatosis.

Journal: Expert opinion on drug delivery

Published: January 19, 2022

Properties of rapamycin solid lipid nanoparticles for lymphatic access through the lungs & part II: the effect of nanoparticle charge.

Properties of rapamycin solid lipid nanoparticles for lymphatic access through the lungs & part II: the effect of nanoparticle charge.

Journal: Nanomedicine (London, England)

Published: August 20, 2020

Delivery of pDNA to lung epithelial cells using PLGA nanoparticles formulated with a cell-penetrating peptide: understanding the intracellular fate.

Delivery of pDNA to lung epithelial cells using PLGA nanoparticles formulated with a cell-penetrating peptide: understanding the intracellular fate.

Journal: Drug development and industrial pharmacy

Published: February 20, 2020

Inhaled rapamycin solid lipid nano particles for the treatment of Lymphangioleiomyomatosis.

Inhaled rapamycin solid lipid nano particles for the treatment of Lymphangioleiomyomatosis.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: April 05, 2019

Nanotoxicologic Effects of PLGA Nanoparticles Formulated with a Cell-Penetrating Peptide: Searching for a Safe pDNA Delivery System for the Lungs.

Nanotoxicologic Effects of PLGA Nanoparticles Formulated with a Cell-Penetrating Peptide: Searching for a Safe pDNA Delivery System for the Lungs.

Journal: Pharmaceutics

Published: October 24, 2018

Delivery of pDNA Polyplexes to Bronchial and Alveolar Epithelial Cells Using a Mesh Nebulizer.

Delivery of pDNA Polyplexes to Bronchial and Alveolar Epithelial Cells Using a Mesh Nebulizer.

Journal: Pharmaceutical research

Published: April 05, 2018

Lymphangioleiomyomatosis: Current understanding and potential treatments.

Lymphangioleiomyomatosis: Current understanding and potential treatments.

Journal: Pharmacology & therapeutics

Published: December 30, 2015

Inhalable tranexamic acid for haemoptysis treatment.

Inhalable tranexamic acid for haemoptysis treatment.

Journal: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Published: February 03, 2015

Doxycycline reduces the migration of tuberous sclerosis complex-2 null cells - effects on RhoA-GTPase and focal adhesion kinase.

Doxycycline reduces the migration of tuberous sclerosis complex-2 null cells - effects on RhoA-GTPase and focal adhesion kinase.

Journal: Journal of cellular and molecular medicine

Published: September 29, 2014

Novel drug targets for asthma and COPD: lessons learned from in vitro and in vivo models.

Novel drug targets for asthma and COPD: lessons learned from in vitro and in vivo models.

Journal: Pulmonary pharmacology & therapeutics

Published: January 31, 2014

Therapeutic strategies in lymphangioleiomyomatosis (LAM).

Therapeutic strategies in lymphangioleiomyomatosis (LAM).

Journal: Respiratory investigation

Published: January 07, 2014

LF-15 & T7, synthetic peptides derived from tumstatin, attenuate aspects of airway remodelling in a murine model of chronic OVA-induced allergic airway disease.

LF-15 & T7, synthetic peptides derived from tumstatin, attenuate aspects of airway remodelling in a murine model of chronic OVA-induced allergic airway disease.

Journal: PloS one

Published: August 29, 2013

Showing 1-12 of 23

Last Updated: 09/26/2026